Unfortunately, developing safer and more effective targeted therapies against high-risk neuroblastoma has been challenging due to the low incidence of targetable recurrent mutations20–22, although a small fraction of patients with ALK mutations are highly responsive to ALK inhibitors23. This evidence concerns the gene ALK and neuroblastoma.